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Abstract
Background: To evaluate anti-prostate cancer effects of a chimeric tumor-targeted killer protein.
Methods: We established a novel fusion gene, immunocasp-3, composed of NH2-terminal leader sequence fused with
an anti-prostate-specific membrane antigen (PSMA) antibody (J591), the furin cleavage sequences of diphtheria toxin
(Fdt), and the reverse coding sequences of the large and small subunits of caspase-3 (revcaspase-3). The expressing
level of the immunocasp-3 gene was evaluated by using the reverse transcription-PCR (RT-PCR) and western blot
analysis. Cell viability assay and cytotoxicity assay were used to evaluate its anti-tumor effects in vitro. Apoptosis was
confirmed by electron microscopy and Annexin V-FITC staining. The antitumor effects of immunocasp-3 were assessed
in nude mice xenograft models containing PSMA-overexpressing LNCaP cells.
Results: This study shows that the immunocasp-3 proteins selectively recognized and induced apoptotic death in PSMA-
overexpressing LNCaP cells in vitro, where apoptotic cells were present in 15.3% of the cells transfected with the
immunocasp-3 expression vector at 48 h after the transfection, in contrast to 5.5% in the control cells. Moreover, LNCaP
cells were significantly killed under the condition of the co-culture of the immunocasp-3-secreting Jurkat cells and more
than 50% of the LNCaP cells died when the two cell lines were co-cultured within 5 days. In addition, The expression of
immunocasp-3 also significantly suppressed tumor growth and greatly prolonged the animal survival rate in vivo.
Conclusion: A novel fusion gene, immunocasp-3, may represent a viable approach to treating PSMA-positive
prostate cancer.
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Background
Prostate cancer is one of the most prevalent malignancy
among males in Western countries [1]. Androgen abla-
tion therapy are typically used to treat metastatic pros-
tate cancer and advanced prostate cancer [2]. However,
most of prostate cancer eventually develop to castration
resistant prostate cancers(CRPC),then progressing rap-
idly [3]. Therefore, it is urgent to develop new molecule-
targeted therapies.
Prostate-specific membrane antigen (PSMA) is a type
II membrane glycoprotein of 100 kD, containing a trans-
membrane domain,a short intracellular segment and an
extensive extracellular domain [4]. The expression of
PSMA was independent of androgen, which was in-
creased along with disease progression and reached to
highest level in CRPC [5–7]. Moreover, the expression
of PSMA is abundant in new vessels associated with the
tumor but not in normal vessels [8–11]. Considering
these points, the combination of gene therapy with anti-
PSMA antibody represents an ideal treatment measure.
Caspase-3, one of critical cysteine protease family
members, takes an important part in the signal transduc-
tion pathways that mediate apoptosis in mammalian
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cells [12]. Cleavage of immunotoxins was mediated by
Furin, which was a rate-limiting step for several secreted
proteins to produce cytotoxic activity [13]. Wang tao et
al. described the construction and characterization of
e23sFv-Fdt-revcaspase 3 containing the furin cleavage
sequences (Diphtheria toxin, A187GNRVRRSVG196, Fdt)
and concluded that the activity of immunocasp-3 pro-
teins is comparable to that of PEA II-caspase 3, as they
contain much less exogenous fragments [14].
To develop a more effective and specific agent for an-
titumor therapy, we established a novel fusion gene,
immunocasp-3 in this work, which was composed of
NH2-terminal leader sequence fused with an anti-PSMA
antibody (J591), the furin cleavage sequences of diph-
theria toxin (Fdt), and the reverse coding sequences of
the large and small subunits of caspase-3 (revcaspase-3)
(Fig. 1a). The antitumor activities of immunocasp-3 and
immunocasp-3 -secreting lymphocytes were evaluated in
vitro and in vivo.
Methods
Cells lines
Two human prostate adenocarcinoma cell lines (LNCaP
cells and PC-3 cells) and human Jurkat cells (American
Type Culture Collection, Rockville, MD) were cultured in
RPMI 1640 medium supplemented with 10% heat-
inactivated fetal bovine serum. The response to PSMA for
LNCaP and PC-3 cells was positive and negative, respect-
ively, which has been confirmed in the previous study [15].
Antibodies and plasmids
The hybridoma of J591 was purchased from the American
Type Culture Collection (Rockville, MD). The plasmid
pCMV-Fdt-revcaspase 3 was provided by Dr. Angang
Yang (Fourth Military Medical University, Xi An, China).
Mice
Four-to-six-week-old male nude mice, obtained from the
Laboratory Animal Research Center of Fourth Military
Medical University. All animal experiments were fully
approved by the Administrative Committee of Experi-
mental Animal Care and Use of Fourth Military Medical
University, and conformed to the National Institute of
Health guidelines on the ethical use of animals.
Plasmids construction
A set of primers to amply the whole variant region se-
quences of heavy chain(VH) and light chain (VL) of mur-
ine antibodies were used to acquire VH and VL gene from
hybridoma J591. HindIII, NotI site sequences, and a signal
peptide sequence (MKHLWFFLLLVAAPRWVLS) were
incorporated into J591 fragments by PCR. Fdt-revcaspase
3 was amplified by PCR using a pCMV-Fdt-revcaspase 3
plasmid as the template. The establishment of the recom-
binant genes was involved in the sequential fusion of the
genes, which could encode J591, Fdt, and revcaspase 3.
The recombinant genes were cloned downstream in the
expression vector pCMV (Fig. 1a). The vector sequences
were validated by DNA sequencing.
Cell transfection
Twenty-four hours prior to transfection, LNCaP cells
and PC-3 cells were seeded in 24-well plates at a density
of 1 × 105 cells per well. The transfection was performed
by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA)
according to the standard procedure of the kit. the cells
were selected in the medium consisting of 800 μg/
ml G418 (Invitrogen, Carlsbad, CA) for two to three
weeks. The cells were cultured in the medium consisting
of 800 μg/ml G418 (Invitrogen, Carlsbad, CA) for two
more weeks to select stable transfection.
Fig. 1 Expression of immunocasp-3 in PC-3 and LNCaP cells. a: Schematic diagram of immunocasp-3 comprising signal sequence, an anti-PSMA
antibody (J591), the furin cleavage sequences of diphtheria toxin (Fdt), and reversed caspase-3 (revcaspase-3). MTT assay of PC-3 (b) and LNCaP
cells (c) transfected with immunocasp-3
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Cell viability assay
The viability of the cells was assessed using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) reduction assay. In the MTT assay, the yellow
tetrazolium salt (MTT) is reduced in metabolically active
cells to form insoluble purple formazan crystals, which
are solubilized by the addition of a detergent. The color
can then be quantitated by spectrophotometry. The cells
transfected with the immunocasp-3 gene were cultured
in 96-well plates for 24 to 96 h. Cells were then incu-
bated with 20 μL of MTT (1.5 mg/mL; Sigma-Aldrich)
per well for 4 h at 37 °C. Cells were centrifuged at
800 rpm for 10 min, and then 150 μL of DMSO was
added and mixed by gentle pipetting to solubilize the
cells. The optical density of the solution was read at
490 nm using a Universal Microplate Reader (Bio-Tek
Instruments, Inc.).
Western blot analysis
We separated The lysates of transfected cells and the
serum-free supernatant fluids of cells transfected with
immunocasp-3 permanently by SDS-PAGE. Then pro-
teins of cells were blotted onto polyvinylidene difluoride
membranes (Amersham Pharmacia Biotech), and then
we incubated these membranes with primary antibodies
which recognize caspase-3 (1:500; BD PharMingen) at
4 °C in PBST overnight. Next, we washed out the pri-
mary antibodies and changed to horseradish peroxidase-
conjugated secondary antibody (1:2,000; ZhongShan), in-
cubating for 2 h at room temperature. Immunoreactive
bands were detected by chemiluminescence kit (Pierce).
Electron microscopy
Pellets of cells were fixed with with 2.5% glutaraldehyde
in 0.1 mol/L sodium phosphate buffer (pH 7.4) for 2 h
at 4 °C. Then after being washed 3 times, and they were
fixed at second time in 1% osmic acid in phosphate buf-
fer before scrapping, dehydration, and embedding. Ultra-
thin sections mounted on 200 mesh grid were examined
in a GEM-2000EX electron microscope.
Cytotoxicity assay in vitro
Transwell filters (Costar), (diameter: 12 mm, pore size:
0.40 μm), which separate the cells but not large molecules,
were used for the cocultivation assay. Tumor cells overex-
pressing PSMA (LNCaP) and control cells expressing un-
detectable PSMA (PC-3) were placed at the bottom
chamber, and the transfected Jurkat cells were placed at
the top chamber. Viable cells at the bottom chambers
were numbered by trypan blue exclusion at the indicated
time points after cocultivation. The percentages of cell
killing were calculated as follows: 1 - (the number of cells
cocultured with stably transfected Jurkat/the number of
cells cocultured with Jurkat controls) × 100%.
Antitumor activity of immunocasp-3 in vivo
Four-to-six-week-old male nude mice were inoculated
with 2 × 106 human prostate cancer LNCaP cells by ad-
ministering a subcutaneous injection of the cells in the
right hind flank. Tumors were allowed to grow until they
reached a diameter of 5–7 mm (day 0). The mice were
then randomly divided into different treatment groups
of 5 mice each. One group of mice received 6 doses
(twice a week) of 10 μg of pCMV-J591-Fdt-revcaspase 3
mixed with lipofectamine as intramuscular injections ad-
ministered in the right posterior limb. Another group of
5 mice received 3 weekly intravenous injections of 2 ×
106 Jurkat-J591-Fdt-revcaspase 3 cells. The control
group was injected with either liposome-mixed empty
pCMV vector or unmodified Jurkat cells. Tumor growth
was monitored with measurement of 2 perpendicular
tumor diameters every 3 days using a caliper, and the
volume of the tumor in mice was calculated by formula:
tumor volume = (width)2 × length/2. The survival time of
the mice was assessed. The mice were then sacrificed by
cervical dislocation and dissected, tissues were washed
and fixed in 10% neutral-buffered formalin, and then
embedded in paraffin. These paraffin-embedded tissue
sections were dewaxed, hydrated, incubated in 0.3%
methanol-H2O2 for 20 min to remove endogenous per-
oxidase and then stained with rabbit anti-human active
caspase-3, as described above.
Statistical analysis
Statistical analysis was performed using the SPSS12.0
software package for Windows (SPSS). Survival rates
were analyzed by the Kaplan-Meier method, and inter-
group comparisons were made using the log-rank test.
Statistical significance was defined as P≦0.05.
Results
Immunocasp-3 fusion proteins expressed in PC-3 and
Jurkat cells
PC-3 cells were transiently transfected with the
immunocasp-3 expression vector or the pCMV void vec-
tor. Translocation was evaluated indirectly by measuring
the degree of caspase-3-induced cytotoxicity. The prolifer-
ation properties of immunocasp-3-expressing PC-3 cells
were similar to those of cells transfected with the pCMV
void vector, which suggests that the expression of the
immunocasp-3 fusion protein was not toxic (Fig. 1b).
CD4+ Jurkat cells were then transfected with the
immunocasp-3 expression vector and stable-expression
cells were selected by the G418 selection method; the
expression of the vector was expected to induce these
cells to secrete the targeted protein, which in turn would
kill PSMA-overexpressing tumor cells. The expression of
the immunocasp-3 gene was detected by reverse
transcription-PCR (RT-PCR) with primers specific to
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anti-PSMA antibody fragment (J591) and Fdt-
revcaspase 3 (Fig. 2a). The expression and secretion
of fusion proteins were confirmed by western blot for
cell culture supernatants (Fig. 2b). Consequently, the
immunocasp-3-modified Jurkat cells remained alive
and showed similar growth and proliferation proper-
ties to those of unmodified cells (Fig. 2c), suggesting
that the expression of the chimeric protein is associ-
ated with low toxicity.
Immunocasp-3 fusion proteins specifically kill PSMA-
overexpressing tumor cells in vitro
Fusion proteins were transiently expressed in PSMA-
positive LNCaP and PSMA-negative PC-3 cells. Cell
death was observed apparently in LNCaP (Fig. 1c) cells
but not in PC-3 cells at 48 h after transfection. Cytotox-
icity was not due to the immunocasp-3 secretion, but ra-
ther the result of PSMA expression on the surface of
LNCaP cells. Typical apoptotic changes were observed
Fig. 2 Detection of immunocasp-3 protein secreted by genetically modified Jurkat cells. a: Genomic DNA was isolated from the immunocasp-3-
modified Jurkat cell clones and analyzed by PCR: J591 (lane 1); revcaspase-3 (lane 2); β-actin (lane 3), respectively. b: Western blot analysis of the
concentrated cell culture medium obtained from Jurkat cells stably transfected with the immunocasp-3 gene. Blots were probed with the anti-
caspase-3 antibody. c: Growth and proliferation characteristics of Jurkat cells transfected with immunocasp-3 or unmodified Jurkat cells
Fig. 3 Immunocasp-3 fusion proteins inhibit the growth of LNCaP cells. a: Electronic microscopy of LNCaP 48 h after transfection of
immunocasp-3. b: 48 h after transfection, LNCaP cells were subjected to Annexin V-FITC staining concomitant with 4,6-diamidino-2-phenylindole
nucleus staining and analyzed by flow cytometry. c: LNCaP cells were cocultured with immunocasp-3-expressing Jurkat cells for the indicated
time points, and the percentages of killing were calculated
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in cells expressing immunocasp-3 by the electronic
microscope, including chromatin condensation and mar-
gination at the nuclear periphery, cellular shrinkage and
blebbing, and formation of apoptotic bodies (Fig. 3a).
Moreover, using FITC-annexin V staining of the cells, it
was revealed that apoptotic cells were present in 15.3%
of the cells transfected with the immunocasp-3 expres-
sion vector at 48 h after the transfection (Fig. 3b), in
contrast to 5.5% in the control cells, a percentage which
was higher than that in the control cells. The genetically
modified Jurkat cells were then cocultivated in vitro
with PSMA-positive LNCaP and PSMA-negative PC-3
cells. The ratio of Jurkat: target cells was adjusted to
3:1, basing on pilot experiments of optimal ratio for
cell killing. As shown in Fig. 3c, a significant number
of LNCaP cells, but not PC-3 cells, were killed by
immunocasp-3-secreting Jurkat cells. More than 50%
of the cells had died within 5 days of coculture, and
additional killing of PSMA-overexpressing tumor cells
was seen after longer times.
Taken together, we conclude that immunocasp-3 pro-
teins are capable of recognizing and killing PSMA-
positive LNCaP cells, but not PSMA-negative PC-3
cells in vitro.
Immunocasp-3 fusion proteins effectively suppress the
growth of PSMA-overexpressing tumor cells in vivo and
prolongs survival in nude mice
The in vivo antitumor activity of immunocasp-3 in nude
mice xenograft models containing PSMA-overexpressing
LNCaP cells were assessed by measuring the tumor size
and animal survival rate. LNCaP cells were subcutane-
ously inoculated into nude mice to form solid tumors.
Murine xenograft models were randomly divided into
two treatment groups. One group of mice were received
6 doses of 10 μg of pCMV-J591-Fdt-revcaspase 3, or
empty pCMV every 3 days over the course of the study.
Another group of prostate cancer-bearing mice received 3
weekly intravenous. injections of 2 × 106 Jurkat cells ex-
pressing J591-Fdt-revcaspase-3 or unmodified Jurkat cells.
Both the vector-lipofectamine-treated group and Jurkat-
cell-treated groups showed greater decrease in tumor vol-
ume and longer survival time than controls (Fig. 4a and b).
Meanwhile, Jurkat-cell-treated group was more efficient
Fig. 4 The antitumor activity of immunocasp-3 on PSMA-overexpressing tumors in vivo. a: Tumor volume and tumor growth curves in mice
injected with lipofectamine-encapsulated immunocasp-3 gene or pCMV plasmid or with immunocasp-3 gene-modified Jurkat cells or control
Jurkat cells. b: Survival of mice after treatment, as described in a. c: Nude mice with LNCaP tumor received 3 weekly intravenous. injections of
2 × 106 immunocasp-3 gene-modified Jurkat cells. Tissues were then subjected to immunohistochemical analysis with an anti-caspase-3 antibody
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than the vector-lipofectamine group in reducing tumor size
(P < 0.05), suggesting that this strategy of gene administra-
tion results in more effective and stable antitumor activities
in LNCaP xenografts. Immunohistochemical analysis also
confirmed the presence of caspase-3 activity in tumors
treated with Jurkat cells expressing J591-Fdt-revcaspase 3,
but not in the normal tissues (Fig. 4c).
Discussion
Many strategies have been designed to kill cancer cells
[16–18]. Because of its restricted and abundant surface ex-
pression on prostate cancer cells, PSMA constitutes an at-
tractive target for immunotherapies against prostate
cancer. Many papers have already reported that the com-
bination of gene therapy and anti-PSMA antibody receives
an ideal therapeutic result [19–24]. Indeed, the antibody
used in this study, J591, has been previously used for the
treatment of prostate cancer cells [23, 25–29].
Wild-type caspase-3 consists of an NH2-terminal pro-
domain, a large subunit, and a small subunit. However,
active caspase-3, which is constructed with the reverse
order of the subunits [30], can induce apoptosis of
tumor cells without apoptotic signals; these properties
make active caspase-3 an attractive candidate molecule
for gene therapy. In this study, the caspase 3 gene was
generated by reversing the order of the coding sequences
for the large and small subunits [31]. To achieve suc-
cessful proapoptotic gene therapy for prostate cancer
cells, it is necessary to devise a gene construct that ex-
presses the proapoptotic gene selectively in the prostate
cells. Therefore, we generated a novel immunocasp-3
gene by fusing a leader sequence, an anti-PSMA anti-
body (J591) and the furin cleavage sequences of diph-
theria toxin (Fdt) to the active revcaspase-3 [14]. The
results of our in vitro and in vivo studies revealed that
the resultant protein, immunocasp-3, killed PSMA-
overexpressing tumor cells, but not PSMA-negative
cells. PC-3 cells are PSMA-negative tumor cells.
Immunocasp-3 fusion proteins secreted in the culture
media cannot enter PC-3 cells via receptor-mediated
endocytosis, and thus cause no damage. Our results
showed that PC-3 cells expressing recombinant
Immunocasp-3 fusion proteins proliferate normally.
Once internalized by PSMA-overexpressing tumor cells
such as LNCaP cells, immunocasp-3 proteins are ex-
posed to a low-pH environment in the endosome, where
the peptide bond in the Fdt domain is cleaved by furin.
Then immunocasp-3 proteins release COOH-terminal
fragments, which consequently translocate to the cytosol
and induce PSMA-overexpressing tumor cells to apop-
tosis. Both injection of lipofectamine-encapsulated
immunocasp-3 and infusion of immunocasp-3 gene-
modified Jurkat cells could suppress tumors due to con-
tinuous secretion of the killer protein and its diffusion
through lymph fluid and blood. However, compared with dir-
ect injections of lipofectamine-encapsulated immunocasp-3,
the applyment of immunocasp-3 gene-modified Jurkat cells
may be a more effective and convenient therapeutic method,
which simplified the procedure like protein purification.
Moreover, caspase-3 proteins were endogenous human
proteins that not only kill prostate cancer cells in a physio-
logical manner, but also resulted in relatively weak im-
munogenicity and minor general toxicity over repeated
administrations. However, because of immunogenicity of
murine antibodies, fully human antibodies could become
necessary.
Conclusions
The newly immunocasp-3 is both highly specific and ef-
fective against PSMA-overexpressing prostate cancer
cells. Treatment using this gene merits further investiga-
tion and consideration as a molecularly targeted thera-
peutic measure for prostate cancers.
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